title: Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048-079 Trials).
abstract: OBJECTIVE
  Interleukin (IL)-2 therapy leads to significant CD4 cell increases in HIV-infected patients. Since phase III trials are ongoing, studies supporting the long-term feasibility of this strategy are needed.
  
  
  METHODS
  We studied the long-term outcomes of 131 patients treated with IL-2 in two studies initiated either before (ANRS 048) or following (ANRS 079) the advent of HAART.
  
  
  RESULTS
  At the last assessment (median follow-up 3.4 years), these patients experienced a gain of 428 cells/microl and a decrease in plasma HIV RNA to 1.70 log10 copies/ml. In both studies, high CD4 cell counts were maintained with a median of ten 5-day cycles of subcutaneous IL-2. Median time since the last cycle was 2 years. At last assessment, 59% of 048 patients maintained a non-HAART regimen. Detailed analysis at week 170 showed that median CD4 cell counts were 856 (048) and 964 (079) cells/microl. This corresponded to a gain from baseline of 515 (048) and 627 (079) cells/microl. The median viral load decreases from baseline and corresponded to 1.70 (048) and 1.88 (079) log10 copies/ml. Comparisons across the studies showed that CD4 gains and viral load changes were similar whether HAART or non-HAART was used. The frequency of cycling, but not CD4 cell counts, viral loads or antiviral regimen at baseline, was predictive of long-term CD4 gain (P = 0.03).
  
  
  CONCLUSIONS
  Altogether, these observations support IL-2 as a long-term therapeutic strategy in HIV infection.
authors.affiliation: INSERM SC10, Villejuif, France.
authors.forename: Christine
authors.initials: C
authors.lastname: Durier
authors.forename: Catherine
authors.initials: C
authors.lastname: Capitant
authors.forename: Anne-Sophie
authors.initials: AS
authors.lastname: Lascaux
authors.forename: Cécile
authors.initials: C
authors.lastname: Goujard
authors.forename: Eric
authors.initials: E
authors.lastname: Oksenhendler
authors.forename: Isabelle
authors.initials: I
authors.lastname: Poizot-Martin
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Viard
authors.forename: Laurence
authors.initials: L
authors.lastname: Weiss
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Netzer
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Delfraissy
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Aboulker
authors.forename: Yves
authors.initials: Y
authors.lastname: Lévy
mesh_terms: D000293:Adolescent; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D002908:Chronic Disease; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007376:Interleukin-2 / Q000008:administration & dosage*; D008134:Long-Term Care / Q000379:methods; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D007376:Interleukin-2; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors